Eli Lilly is conducting a US-Based Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab (Taltz)
To participate in your local study, please contact (949) 844-0442 or fill out the form below.
Protocol # I1F-MC-B018
Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.